Skip to main content
SpringerLink
Log in

Hematopoietic Growth Factors: Supportive and Priming Effects in AML

  • Conference paper
Acute Leukemias VII

Part of the book series: Haematology and Blood Transfusion / Hämatologie und Bluttransfusion ((HAEMATOLOGY,volume 39))

  • 120 Accesses

Abstract

Growth factors have been administered after chemotherapy in 12 studies. Eight studies showed benefits in neutropenia and seven studies benefits in infections or survival or remissions. Clinical benefits are mainly found in high-risk patients. There are five negative studies according to major benefits, all five studies using E. coli produced GM-CSF. Growth factors before or together with chemotherapy were given in nine studies with trends to more remissions in one and to longer disease-free survival in three studies. Extending the priming strategy to more chemotherapy courses than having been done so far may further improve the antileukemic effect.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ohno R, Tomonaga M, Kobayashi T et al. (1990) Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323: 871–877

    Article  PubMed  CAS  Google Scholar 

  2. Dombret H, Chastang C, Fenaux, et al. (1995) A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 22: 1678–1683

    Article  Google Scholar 

  3. Heil G, Hoelzer D, Sanz MA et al. (1995) Results of a randomized double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukemia. Blood 86 (suppl 1): 267a

    Google Scholar 

  4. Link H, Wandt H, Schönrock-Nabulsi P et al. (1996) G-CSF (Lenograstim) after chemotherapy for acute myeloid leukemia: A placebo controlled trial. Blood 88 (suppl 1): 666a

    Google Scholar 

  5. Büchner Th, Hiddemann, W, Koenigsmann M et al. (1991) Recombinant human granulocytemacrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78: 1190–1197

    PubMed  Google Scholar 

  6. Rowe, JM, Andersen J, Mazza JJ et al. (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage colony stimulating factor (GM-CSF) in adult patients (> 55–70 years) with acute myelogenous leukemia (AML). A study of the Eastern Cooperative Oncology Group (E1490). Blood 86: 457–462

    PubMed  CAS  Google Scholar 

  7. Ohno R, Miyawaki S, Hatake K et al. (1995) Macrophage colony stimulating factor (M-CSF) reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia (AML): A double-blind controlled study. Blood 86 (suppl 1): 266a

    Google Scholar 

  8. Estey EH, Dixon D, Kantarjian HM et al. (1990) Treatment of poor-prognostic newly diagnosed acute myeloid leukemia with Ara-C and recombinant human granulocyte-macrophage colony stimulating factor. Blood 75: 1766–1769

    PubMed  CAS  Google Scholar 

  9. Witz F, Harousseau JL, Sadoun D et al. (1997) GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia (AML). Hematol Blood Transfus 40: 852–856

    Google Scholar 

  10. Stone RM, Berg DT, George SL et al. (1995) Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 332: 1671–1677

    Article  PubMed  CAS  Google Scholar 

  11. Löwenberg B, Suciu S, Zittoun R et al. (1995) GM-CSF during as well as after induction chemotherapy (CT) in elderly patients with acute myeloid leukemia (AML). The EORTC/HOVON phase III trial (AML 11). Blood 86 (suppl 1): 433a

    Google Scholar 

  12. Zittoun R, Suciu S, Mandelli F et al. (1996) Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 14: 2150–2159

    PubMed  CAS  Google Scholar 

  13. Griffin JD, Young D, Hermann F et al. (1986) Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 67: 1448–1453

    PubMed  CAS  Google Scholar 

  14. Reuter C, Auf der Landwehr U, Schleyer E et al. (1994) Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor. Leukemia 8: 217–225

    PubMed  CAS  Google Scholar 

  15. Zühlsdorf M, Busemann C, Weißpfennig S et al. (1994) Priming with rhGM-CSF or rh-IL-3 for AML progenitors versus CFU-GM in vivo and in vitro: Significant increase in therapeutic ratio for cytosine arabinoside. Proc AACR 85: 211

    Google Scholar 

  16. Van Der Lely N, De Witte T, Wessels J et al. (1994) In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity. Ann Hematol 68: 225–232

    Article  PubMed  CAS  Google Scholar 

  17. Koistinen P, Wang C, Curtis JE et al. (1991) Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from Ara-C toxicity. Leukemia 5: 789–795

    PubMed  CAS  Google Scholar 

  18. Lotem J, Sachs L (1992) Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor bl and cancer chemotherapy compounds in myeloid leukemic cells. Blood 80: 1750–1778

    PubMed  CAS  Google Scholar 

  19. Estey E, Hall PT, Kantarjian H et al. (1992) Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose Ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 79: 2246–2255

    PubMed  CAS  Google Scholar 

  20. Heil G, Chadid L, Hoelzer D et al. (1995) GMCSF in a double-blind randomized, placebo controlled trial on therapy of adult patients with de novo acute myeloid Leukemia (AML). Leukemia 9: 3–9

    PubMed  CAS  Google Scholar 

  21. Büchner Th, Hiddemann W, Wörmann B et al. (1996) Age and karyotype-dependent effect of GM-CSF multiple course priming in AML. Blood 88 (suppl 1): 214a

    Google Scholar 

  22. Baer M.R., Bernstein SH, Brunetto VL et al. (1993) In vivo recombinant human G-CSF priming in previously untreated acute myeloid leukemia. Blood 26 Suppl 1: 328a

    Google Scholar 

  23. Estey E, Thall P, Andreeff M et al. (1994) Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12: 671–678

    PubMed  CAS  Google Scholar 

  24. Ohno R, Naoe T, Kanamaru A et al. (1994) A double-blind study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 83: 2086–2092

    PubMed  CAS  Google Scholar 

  25. Bettelheim P, Valent P, Andreeff M et al. (1991) Recombinant human granulocyte-macrophage colony-stimulating factor in de novo acute myeloid leukemia. Blood 77: 700–711

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology, University of Münster, Germany

    T. Büchner, W. Hiddemann, M. Zühlsdorf, B. Wörmann, J. Aswald, S. Aswald, G. Maschmeyer, W.-D. Ludwig & M.-C. Sauerland

Authors
  1. T. Büchner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Hiddemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Zühlsdorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Wörmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Aswald
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Aswald
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Maschmeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. W.-D. Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M.-C. Sauerland
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

A. Heinecke for the AMLCG

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, University of Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Germany

    W. Hiddemann  & B. Wörmann  & 

  2. Department of Internal Medicine, USA

    T. Büchner

  3. Department of Pediatrics, University of Münster, Albert-Schweitzer-Straße 33, 48149, Münster, Germany

    J. Ritter  & U. Creutzig  & 

  4. Dept. of Hematology, University of Texas, Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Tx., USA

    M. Keating MD PhD  & W. Plunkett MD PhD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Büchner, T. et al. (1998). Hematopoietic Growth Factors: Supportive and Priming Effects in AML. In: Hiddemann, W., et al. Acute Leukemias VII. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 39. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71960-8_40

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-71960-8_40

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-71962-2

  • Online ISBN: 978-3-642-71960-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation